Latest On Daxor Corporation (DXR):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-22 21:05 EST | News | Daxor shares tumble after pricing stock offering at discount | N/A |  |
| 2023-03-07 03:42 EST | News | Daxor Corporation (DXR) Q4 2022 Earnings Call Transcript | N/A | |
| 2022-11-15 18:06 EST | News | Daxor to raise $2M in stock offering | N/A | |
| 2022-11-15 01:17 EST | News | Daxor tumbles 11% aftermarket on proposed stock offering | N/A | |
| 2022-08-26 20:18 EST | News | Daxor Corporation (DXR) Q2 2022 Earnings Call Transcript | N/A | |
About Daxor Corporation (DXR):
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching read more... the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
General
- Name Daxor Corporation
- Symbol DXR
- Type Common Stock
- Exchange NYSE MKT
- Currency USD
- Country USA
- SectorFinancial Services
- IndustryAsset Management
- Fiscal Year EndDecember
- IPO Date1992-03-17
- Gic SectorHealth Care
- Gic GroupHealth Care Equipment & Services
- Gic IndustryHealth Care Equipment & Supplies
- Gic SubIndustryHealth Care Equipment
- Web URLhttp://www.daxor.com
Valuation
- Trailing PE 118.75
- Price/Sales (Trailing 12 Mt.) 98.79
- Price/Book (Most Recent Quarter) 3.13
Financials
- Most Recent Quarter 2020-12-31
- Operating Margin -128%
- Return on Assets -1%
- Return on Equity -12%
- Revenue 264440
- Earnings Per Share $0.05
- Revenue Per Share $0.07
- Gross Profit 264440
- Quarterly Earnings Growth -22.3%
Highlights
- Market Capitalization 51.28 million
- Analyst Target Price $22
- Book Value Per Share $3.89
Share Statistics
- Shares Outstanding 4.03 million
- Shares Float 1.32 million
- % Held by Insiders 6988%
- % Held by Institutions 5.22%
- Shares Short 14452
- Shares Short Prior Month 13568
- Short Ratio 0.9
Technicals
- Beta -1.01
- 52 Week High $20.44
- 52 Week Low $11.02
- 50 Day Moving Average 12.66
- 200 Day Moving Average 13.65
Dividends
- Dividend Date 2018-01-12
- ExDividend Date 2018-01-05
- Dividend Per Share $0.03
- Dividend Yield 0%
Daxor Corporation (DXR) Dividend Calendar:
DXR's last dividend payment was made to shareholders on January 12, 2018.
Daxor Corporation (DXR) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Daxor Corporation (DXR) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Daxor Corporation (DXR) Chart:
Daxor Corporation (DXR) News:
Below you will find a list of latest news for Daxor Corporation (DXR) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Daxor Corporation (DXR) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Daxor Corporation (DXR) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-22 | 40-17F2 (Certificate of accounting of securities in custody of management investment companies [Rule 17f-2]) | |
| 2020-10-21 | NPORT-P (Monthly Portfolio Investments Report on Form N-PORT (Public)) | |
| 2020-10-05 | 8-K (Current report) | |
| 2020-09-16 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-09-01 | N-PX (Annual Report of proxy voting record of management investment companies) | |
| 2020-08-21 | N-CSRS (Certified Shareholder Report, Semi-Annual) | |
| 2020-08-03 | 497 (Definitive materials) | |
| 2020-08-03 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-29 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-21 | 8-K (Current report) | |
| 2020-07-21 | 497 (Definitive materials) | |
| 2020-07-20 | 497 (Definitive materials) | |
| 2020-07-16 | 8-K (Current report) | |
| 2020-07-15 | 8-K (Current report) | |
| 2020-07-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-14 | EFFECT (Notice of Effectiveness) | |
| 2020-07-13 | CORRESP (Correspondence) | |
| 2020-07-13 | POS 8C (Post-effective amendments filed by certain investment companies [Section 8(c)]) | |
Daxor Corporation (DXR) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Daxor Corporation (DXR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 6988%
Institutional Ownership: 522%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-03-22 | Robert J Michel | CHIEF FINANCIAL OFFICER | Buy | 750.00 | 13.02 | 9,765.00 | 3,250.00 | |
| 2019-03-21 | Michael Richard Feldschuh | CEO & President | Buy | 600.00 | 12.36 | 7,417.74 | 153,406.00 | |
| 2019-03-21 | Michael Richard Feldschuh | CEO & President | Buy | 400.00 | 12.40 | 4,960.00 | 153,806.00 | |
| 2019-03-21 | Michael Richard Feldschuh | CEO & President | Buy | 200.00 | 12.20 | 2,440.00 | 154,006.00 | |
| 2018-11-07 | Robert J Michel | CHIEF FINANCIAL OFFICER | Buy | 2,500.00 | 7.42 | 18,550.00 | 2,500.00 | |
| 2018-07-31 | Soren Thompson | VP, Business Development | Buy | 1,000.00 | 5.50 | 5,500.00 | 1,950.00 | |
| 2018-07-13 | Edward Feuer | Director | Buy | 1,500.00 | 6.18 | 9,270.00 | 1,500.00 | |